Axsome Therapeutics, Inc. filed a Form 8-K on November 2, 2026, furnishing a press release announcing its financial results for the three months ended September 30, 2026, and an updated corporate presentation.

Key Highlights

  • Reporting period: Financial results cover the three months ended September 30, 2026.
  • Press release: The company issued a press release on November 2, 2026, announcing its results and providing an operational update, attached as Exhibit 99.1.
  • Corporate presentation: The company updated its corporate presentation and posted it to its website on November 2, 2026, filed as Exhibit 99.2.
  • Filing status: The information in Item 2.02, including Exhibit 99.1, is furnished and "shall not be deemed 'filed'" for purposes of Section 18 of the Securities Exchange Act of 1934, according to the filing.
  • Signatory: The report was signed by Herriot Tabuteau, M.D., President and Chief Executive Officer.

Axsome Therapeutics Announces Q3 2026 Financial Results and Corporate Update

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a Delaware-incorporated company headquartered at One World Trade Center, 29th Floor, New York, New York 10007, filed a current report on November 2, 2026, under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). The filing reports that on November 2, 2026, the company issued a press release covering its financial results for the three months ended September 30, 2026, along with an operational update. That press release is attached to the filing as Exhibit 99.1.

According to the filing, the information furnished under Item 2.02, including Exhibit 99.1, is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, and is not incorporated by reference into other filings unless expressly specified. Separately, under Item 8.01, the company disclosed that it updated its corporate presentation on the same date and posted it to its website; this presentation is filed as Exhibit 99.2 and incorporated by reference into the current report.

The report was signed on behalf of the company by Herriot Tabuteau, M.D., in his capacity as President and Chief Executive Officer. Axsome Therapeutics lists its common stock, par value $0.0001 per share, on the Nasdaq Global Market under the trading symbol AXSM, as stated on the filing's cover page.

What Was Disclosed

Axsome Therapeutics filed an 8-K on November 2, 2026, furnishing a press release on Q3 2026 financial results (Exhibit 99.1) and filing an updated corporate presentation (Exhibit 99.2), with Herriot Tabuteau, M.D. signing as President and CEO.